Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ16014MR)

This product GTTS-WQ16014MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ16014MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10765MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-70
GTTS-WQ7197MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ11722MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ4912MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ4244MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ14900MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ7707MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ4610MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW